Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Blood (2018) 132 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2018-99-114318

Published: 2018

Journal Articles

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Blood (2018) 132 (Supplement 1): 435.

https://doi.org/10.1182/blood-2018-99-116149

Published: 2018

Journal Articles

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Bourras-Rezki Bengoudifa, Hans Weber, PhD, Insa Gathmann, Albert Hoenekopp, MD, Noah Berkowitz, MD PhD

Blood (2018) 132 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2018-99-119394

Published: 2018

Journal Articles

Comprehensive Molecular Profiling of FLT3 -Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

Blood (2018) 132 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2018-99-115842

Published: 2018

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.

Joerg Hasford, Michael Lauseker, Insa Gathmann, Markus Pfirrmann, PhD, Richard A. Larson, MD, François Guilhot, Stephen G O’Brien, Brian J. Druker, Ruediger Hehlmann, Andreas Hochhaus, MD, For the IRIS Study Group, For the German CML Study Group

Blood (2008) 112 (11): 2123.

https://doi.org/10.1182/blood.V112.11.2123.2123

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

Journal Articles

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2008) 111 (8): 4022–4028.

https://doi.org/10.1182/blood-2007-10-116475

Published: 2008

Includes: Supplemental data

Journal Articles

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Andreas Hochhaus, MD, Brian J. Druker, MD, Richard A. Larson, MD, Stephen G. O’Brien, MD, PhD, Insa Gathmann, Francois Guilhot, MD

Blood (2007) 110 (11): 25.

https://doi.org/10.1182/blood.V110.11.25.25

Published: 2007

Journal Articles

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MD, PhD, Tillman Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2007) 110 (11): 1935.

https://doi.org/10.1182/blood.V110.11.1935.1935

Published: 2007

Journal Articles

Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy.

Francois Guilhot, MD, Richard A. Larson, MD, Stephen G. O’Brien, MD, PhD, Insa Gathmann, Brian J. Druker, MD

Blood (2007) 110 (11): 27.

https://doi.org/10.1182/blood.V110.11.27.27

Published: 2007

Journal Articles

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MBChB, PhD, Insa Gathmann, MS, Gilles J. Riviere, PhD, Charlene So, PharmD, Yanfeng Wang, PhD, on Behalf of the IRIS Study Group

Blood (2006) 108 (11): 429.

https://doi.org/10.1182/blood.V108.11.429.429

Published: 2006

Journal Articles

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group

Blood (2006) 108 (11): 2139.

https://doi.org/10.1182/blood.V108.11.2139.2139

Published: 2006

Journal Articles

Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.

Michael W. Deininger, MD, PhD, Hagop M. Kantarjian, MD, Park Byung, Andreas Hochhaus, MD, Charles L. Sawyers, MD, Michele Baccarani, MD, Insa Gathmann, Charlene So, Brian J. Druker, MD, Francois Guilhot, MD

Blood (2005) 106 (11): 1082.

https://doi.org/10.1182/blood.V106.11.1082.1082

Published: 2005

Journal Articles

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.

Carlo Gambacorti, Moshe Talpaz, Charles L. Sawyers, Brian J. Druker, Andreas Hochhaus, Charles A. Schiffer, Francois Guilhot, Dietger W. Niederwieser, Richard M. Stone, John M. Goldman, Manisha Mone, Tillmann Krahnke, Insa Gathmann, Hagop M. Kantarjian

Blood (2005) 106 (11): 1089.

https://doi.org/10.1182/blood.V106.11.1089.1089

Published: 2005

Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD

Blood (2005) 106 (11): 163.

https://doi.org/10.1182/blood.V106.11.163.163

Published: 2005

Journal Articles

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

John Porter, MD, Elliot Vichinsky, MD, Christian Rose, MD, Antonio Piga, MD, Nancy Olivieri, MD, Norbert Gattermann, MD, Johan Maertens, MD, Bertrand Rabault, PhD, Insa Gathmann, MSc, Daniele Alberti, MD

Blood (2004) 104 (11): 3193.

https://doi.org/10.1182/blood.V104.11.3193.3193

Published: 2004

Journal Articles

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias

Oliver G. Ottmann, Brian J. Druker, Charles L. Sawyers, John M. Goldman, Jose Reiffers, Richard T. Silver, Sante Tura, Thomas Fischer, Michael W. Deininger, Charles A. Schiffer, Michele Baccarani, Alois Gratwohl, Andreas Hochhaus, Dieter Hoelzer, Sofia Fernandes-Reese, Insa Gathmann, Renaud Capdeville, Stephen G. O'Brien

Blood (2002) 100 (6): 1965–1971.

https://doi.org/10.1182/blood-2001-12-0181

Published: 2002

Journal Articles

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Blood (2002) 99 (10): 3530–3539.

https://doi.org/10.1182/blood.V99.10.3530

Published: 2002

NARROW

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Comprehensive Molecular Profiling of FLT3 -Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy.

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only